Studying how cancer patients like to learn about genetic results
Part of Cancer, Genetic & congenital clinical trials.
This trial looks at the best ways to give cancer patients their genetic information before a special test called exome analysis. It aims to make sure you get the information in a way that feels right for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a cancer patient who has been asked to join the EXOMA 2 study (which involves a genetic test).
- You need to be available to receive information in different ways (like in person, by phone, etc.).
- You must speak French fluently.
- You must not have had a prior meeting with a genetic counselor about your cancer.
- You must agree to let us record your consultations and interviews for the study.
- You cannot be a genetics professional working in the field.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the tumor’s DNA to help doctors choose the best next treatment for people with advanced cancer. It’s testing whether this “exome” genetic analysis can improve therapeutic decisions for newly treated metastatic or locally advanced solid tumors.
This study uses gene testing on stored tumor tissue (and a blood sample) to help doctors recommend treatment options that may fit your tumor’s specific changes. It may also help avoid certain medicines and share your de-identified data with other researchers.
This trial studies how doing genetic (DNA) testing on your cancer helps doctors choose targeted treatments, and how those treatments affect outcomes. It is for adults whose cancer has not responded to the first standard treatment or who do not have curative options.
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
This Phase 2 study uses a team review of your tumor’s gene test results to help match you with treatments you may benefit from. It’s designed for people whose tumor has specific gene changes that suggest sensitivity to available medicines or may involve inherited (germline) risk.
Hear when a new All Types of Metastatic Solid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.